Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Employees - 65,
CEO - Mr. Guido Baechler,
Sector - Healthcare,
Country - DE,
Market Cap - 18.72M
Altman ZScore(max is 10): -11.03, Piotroski Score(max is 10): 3, Working Capital: $-257148, Total Assets: $15409028, Retained Earnings: $-69328021, EBIT: -25313255, Total Liabilities: $12159802, Revenue: $895479
- Current Price $6.68 - Analyst Target Price $160.00| Ticker | MYNZ |
| Index | - |
| Curent Price | 6.68 |
| Change | 40.04% |
| Market Cap | 18.72M |
| Average Volume | 118.09K |
| Income | -26.30M |
| Sales | 0.90M |
| Book Value/Share | 6.14 |
| Cash/Share | 2.52 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 71 |
| Moving Avg 20days | -0.18% |
| Moving Avg 50days | -25.08% |
| Moving Avg 200days | -66.17% |
| Shares Outstanding | 2.00M |
| Earnings Date | Oct 30 |
| Inst. Ownership | 0.24% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 20.80 |
| Price/Book | 1.09 |
| Price/Cash | 2.65 |
| Price/FCF | - |
| Quick Ratio | 0.91 |
| Current Ratio | 0.97 |
| Debt/Equity | 1.96 |
| Return on Assets | - |
| Return on Equity | - |
| Return on Investment | -595.61% |
| Gross Margin | -72.83% |
| Ops Margin | -2975.47% |
| Profit Margin | -2936.50% |
| RSI | 48.31 |
| BETA(β) | 0.10 |
| From 52week Low | 83.01% |
| From 52week High | -87.54% |
| EPS | -65.57 |
| EPS next Year | -9.20 |
| EPS next Qtr | -3.60 |
| EPS this Year | 63.58% |
| EPS next 5 Year | - |
| EPS past 5 Year | - |
| Sales past 5 Year | 25.92% |
| EPS Y/Y | 11.95% |
| Sales Y/Y | - |
| EPS Q/Q | -1121.45% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | - |
| ATR(14) | 1.29 |
| Perf Week | 24.63% |
| Perf Month | -25.45% |
| Perf Quarter | -16.58% |
| Perf Year | -85.67% |
| Perf YTD | -85.60% |
| Target Price | 160.00 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer